Author

Sara Marín-Liébana

Observed names: Marin-Liebana Sara, S. Marin-Liebana, S. Marín-Liébana, S.M. Liebana

Institution: Hospital Arnau de Vilanova

Observed institutions: Valencia Catholic University Saint Vincent Martyr, Hospital Arnau de Vilanova, Hospital de Manises

ORCID: 0009-0009-9756-0939

Observed ORCID: 0009-0009-9756-0939

OpenAlex ID: A5007291630

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

2018 · J. Garde-Noguera, P. Martin-Martorell, et al. · Clinical & Translational Oncology · 58

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study

2025 · O. Martínez-Sáez, M. Tapia, et al. · ESMO Real World Data and Digital Oncology · 11

Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer

2025 · Sara Marín-Liébana, Paula Llor, et al. · Cancers · 8

Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

2018 · J. Garde-Noguera, P. Martin-Martorell, et al. · Clinical & Translational Oncology · 3

Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor

2026 · José Manuel Pérez-García, Antonio Llombart-Cussac, et al. · Future Oncology

Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor

2026 · José Manuel Pérez-García, Antonio Llombart-Cussac, et al. · Figshare

5P PRE-PHENIX: ctDNA minimal residual disease predicts outcomes in extraordinary responders with HER2-positive metastatic breast cancer on first-line trastuzumab—pertuzumab

2026 · J.J. Iranzo Barreira, M.L. Fernández-Murga, et al. · ESMO Open

134P Impact of pre-operative MammaPrint/BluePrint use for final treatment decisions in patients with stage II/IIIa HR+/HER2- early-stage breast cancer eligible for neoadjuvant chemotherapy: The DETERMIND study

2023 · S. Marin-Liebana, S. Morales, et al. · ESMO Open

Prognostic Impact of Ablative Therapy in Oligometastatic Non-Small-Cell Lung Cancer (NSCLC) with Unresectable Primary Tumor

2019 · Garde-Noguera Javier, Marin-Liebana Sara, et al. · Annals of Lung Cancer

Works count: 9

Citation count: 80

H-index: 3

I10-index: 2